Isofol’s Board of Directors resolve on a fully guaranteed preferential rights issue of approximately SEK 150 million
GOTHENBURG, Sweden, May 7, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the […]
English
Isofol’s drug candidate arfolitixorin receives additional clinical patent approval in the United States
GOTHENBURG, Sweden, May 5, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced approval
Information in relation to COVID-19
GOTHENBURG, Sweden, April 2, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), has since the
Gene expression data from new analysis method supports that a larger proportion of patients will benefit from arfolitixorin
GOTHENBURG, Sweden, March 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that
Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 150 million and a potential over-allotment option of up to approximately SEK 30 million
GOTHENBURG, Sweden, March 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that
The first patient included in Japan in Isofol’s Phase 3 AGENT study
GOTHENBURG, Sweden, February 18 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first
Gene expression analysis method has been validated by a commercial laboratory
GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announced that the method
Over 200 patients now randomized in the Global Phase 3 AGENT Study
GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announced that over 200
The Phase 1/2a study ISO-CC-005 is completed
GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announces that the recruitment
The first patient included in Australia in Isofol’s Phase 3 AGENT study
GOTHENBURG, Sweden, January 24 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first